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Objectives: There is only limited economic data in head-to head comparison between a whole
blood QuantiFERON TB Gold in tube (QFT) and the tuberculin skin test (TST) when screening
and treating for latent tuberculosis infection (LTBI), and no published study to date that takes
into account the predictive value of the two tests.
Methods: Health and economic outcomes of isoniazid preventive treatment (IPT) of close
contacts were compared in a decision tree model to perform a cost-benefit analysis with
respect to isoniazid related hepatotoxicity and early post-exposure TB over a 2-y period, using
the QFT or TST alone or QFT as a confirmatory test for TST results.
Results: Cost of screening and treating for using the QFT alone amounted to V215.79 per close
contact, less than that of dual step-testing (V227.89) or using TST alone (V232.58). Savings
amounted to V12,200 or V16,791 per 1000 close contacts, respectively. QFT based procedures
were most sensitive to low compliance with IPT or increasing price. Costs of dual step
screening was mostly influenced by cost of treating TB disease. When the progression rate
for QFT was lowered to that for the TST in a sensitivity analysis, the relationship between
the strategies remained robust. In addition, costs of the QFT strategy decreased to V165.1,
and those of the dual step strategy to V218.4.
Conclusion: IPT on the basis of using the QFT assay alone produces less cost and reduces more
TB cases than other strategies in a low-incidence setting. These data have implications for the
rational implementation of screening strategies in contact investigation.
ª 2009 Elsevier Ltd. All rights reserved.724578525.
hannover.de (R. Diel).
9 Elsevier Ltd. All rights reservedIntroduction
The objective of latent tuberculosis infection (LTBI)
screening in developed countries is to select subjects for
isoniazid (INH) preventive treatment (IPT), which.
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further MTB transmission. The new IGRA tests, offering
greater specificity than the conventional Tuberculin Skin
Test (TST) in detecting LTBI, and a high level of sensitivity,
provide new possibilities for following that rationale.
Confidence in treating persons at risk for TB on the basis of
IGRA testing should be greater than with TST based testing
since the ability of one at least of those tests, the Quan-
tiFERON TB Gold in tube (QFT) test to identify those most
likely to develop TB disease, has recently been confirmed.1
If INH were harmless, however, there would be little
controversy about offering it to virtually anyone with sus-
pected LTBI. Since it is not, disputes over balancing the
risks and benefits of IPT still remain. The most important
risk of IPT is the risk of INH-induced hepatitis, but to date
no cost effectiveness analysis has included the risk and
costs of hepatitis along with best available evidence with
respect to test-related differences in progression to TB
disease. Implementing a risk-defined IPT policy requires
that primary care providers take action that begins with
identifying and reaching patients who meet the policy’s
criteria. In state-regulated health care systems, value for
money is an essential factor in calculating the reimburse-
ment of diagnostic procedures such as IGRA tests to achieve
that first important step.2
Cost-benefit analysis provides a well established
framework for determining whether IGRA screening and
subsequent IPT provides value for money, as compared to
TST based strategies, weighing their total expected costs
against their total expected benefits in order to identify the
option providing the greatest savings. Whilst cost-effec-
tiveness analyses generally focus on cost per life year
gained (QALYs) using decades or lifetime horizons as a time
frame to be followed up, they do not allow for the analysis
of the relative contribution of the single steps in the
pathway of screening and treating.
To address this issue over the short, butewith respect to
the risk of developing TB e most critical two-year period
following fresh infection, our cost analysis weaves the
results of a recently published prospective study comparing
the outcomes of testing with TSTand with the QFT in respect
to development of TB disease in Germany1 into an economic
context, and incorporates the increasingly recommended
methods of probabilistic sensitivity analysis (PSA).Methods
Briefly, our model uses a decision tree analysis that factors
the probability and cost of each event in the contact
investigation to reach a final cost and probability for each
pathway a contact may possibly follow (Fig. 1). We have
incorporated the procedures as designated in the German
national recommendations3 for contact investigation, and
analyzed the strategies of using QFT or TST testing alone, or
combined TST-QFT testing.
The model incorporates the observation that progression
to TB disease is more likely to occur in QFT positive than in
TST positive subjects.1 It focuses on the two years following
initial screening and includes costing and consideration of
all various events that may occur during INH preventive
therapy, including compliance failure, minor and majorhepatic events, prevention of active disease and other
health outcomes. However, as the superior predictive value
of the QFT needs to be confirmed in larger prospective
studies, a sensitivity analysis was performed (as described
below) in which the rate of progression of the QFT was
equalized to that of the TST to prevent overestimation of
the QFT predictive value.
A major feature of the analysis used was that both
deterministic and probabilistic sensitivity analysis was
applied. In deterministic sensitivity analysis, input vari-
ables are altered along their reasonable range to test effect
on cost outcomes, which has several limitations. While
analysis may use extreme values for several parameters,
this may not capture interactions between multiple inputs
as it is unrealistic for all inputs to be at high or low
extremes. Thus, deterministic multivariate analyses tend to
overestimate uncertainty, and cannot provide statistical
inferences. Probabilistic sensitivity analyses (PSA) address
these problems. Based on a Bayesian second order Monte
Carlo simulation, the principle of PSA is to run the model
a large number of times with different sets of inputs.
Assigning an appropriate statistical (probability) distribu-
tion for all parameters that are not fixed values allows the
model to capture the possible range of outcomes. Mean-
while, for each run, inputs are selected at random from
their statistical distributions and the simulation draws one
value at a time from the feasible range, doing so simulta-
neously for each parameter; by repeating the process many
times a statistical representation of the likely cost
outcomes is created.4,5 We ran 1000 iterations and calcu-
lated mean values and standard deviations.
Details of sources of costings, practices followed, and the
methods of cost-benefit analysis are available at the Online
supplement. Also on-line are detailed references and data
on progression, INH initiation and compliance rates, INH
benefits, effects of partial INH compliance, INH hepatitis
and other effects. Base case inputs, alternative values and
the according type of distribution are shown in Table 1.
Results
Base case results
The costs for each strategy over a 2-y period were assessed
using the decision tree model depicted in Figs. 1e3 and
incorporating the data of Table 1.
On the baseline assumption that about only half of test-
positive contacts (0.51) were willing to start treatment and
incorporating the different progression rates to active TB
disease given test positivity of the TST or the QFTwithin the
2-y time-frame, the cost of QFT alone amounted to V215.79
per close contact, less than that of using TST alone, which
amounted to V232.58. As a result, QFT alone would save
V16,791 per 1000 close contacts screened in comparison to
TST alone (see Table 4).
For the TST, if 95% of the TST results were to be read and
the probability of being TST positive were 0.38, 361
contacts (0.95 380) would be assessed to be TST positive
and 589 contacts would be tested negative (0.95 620).
The results of the remaining 50 contacts who would not
appear for TST reading cannot be determined, but the same
Figure 1 Screening and IPT using the TST. Decision analysis model for predicting the costs and the occurrence of tuberculosis (TB) due to latent TB by screening a cohort of close
contacts and treating the test-positives with INH using the TST strategy (Fig. 1), the QFT strategy (Fig. 2) or dual step-testing (TST followed by QFT, Fig. 3). A decision node (,) is
the decision to test a contact by using the respective screening procedure. Branches from a change node (B) represent the possible outcomes of an event; terminal nodes (9) are
assigned the cost of a prior series of actions and events. Probabilities (p): see Model Specifications; #: complementary probability (all probabilities of chance node’s branches to
sum to 1.0).
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Table 1 List of variable parameters.
Parameter Baseline DSA PSA Results PSA (Mean SD) Source
Probability of starting treatment 0.51 0.20e0.51 Beta (116;111) 0.51 0.01 9,10
Probability of INH-induced hepatitis 0.005 0.0036e0.0052 Beta (95; 20,745) 0.0046 4.8E-05 13,14
TB reduction of after full 9 months IPT course 0.6 95% CI (0.57e0.63) Beta (478;318) 0.60 0.017 14
TB reduction of TB cases after 3 months of IPT 0.216 95% CI (0.13 to 0.30) Beta (21;76) 0.21 0.04 15
Probability of hospitalisation due to
INH-induced hepatitis/1000
0.03 (0.15/5) 0.02 to 0.04 (0.1/5 to 0.2/5) triangular 0.03 0.004 13,17e20
Probability of testing positive
TST positive 0.38 Beta (219;358) 0.38 0.02 1
QFT positive 0.071 Beta (41; 535) 0.071 0.01 1
Cost of PHS screening for LTBI
TST based V117.542 V113.79eV121.29 triangular V117.57V1.52 39
QFT based V145.98 V125.98eV165.98 triangular V145.9V8.55 39
Probability of progression to disease
TST positive 0.0228 Beta (5; 214) 0.023 0.01 1
QFT positive 0.1463 0.0228 uniform 0.085 0.001 1
Cost of INH treatment
9 mo course V223.29 V111.65eV446.58 triangular V335.15V63.97 Calculated
3 mo partial course V73.32 V36.66eV146.64 triangular V110.72V21.20 Calculated
Chest X-ray costa V47.21 V26.32eV47.21 uniform V33.88V4.41 German scale of
fees (GOA¨)
Cost of hepatotoxic side effects
Cost of hospitalisation V1433.6 V1433.6eV2867.2 uniform V2142.17V419.73 German DRG 2009
Cost of death due to hepatitis V3883.6 V3883.6eV7767.2 uniform V5857.63V1108.40 German DRG 2009
Cost of TB disease V8325.72 V8325.72eV16651.44 uniform V9897.37V2618.30 Calculated
a On behalf of the public health service if testpositive contacts refuses INH treatment.
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1842 R. Diel et al.probabilities for being test-positive and test-negative
should be expected as when they were read viz 31 negative
and 19 positive.
Costs of screening of the 361 TST positives amount to
V42,431.94 (361V117.54). If 51% of those, i.e. 184
(184.11) persons, opt for IPT, costs of V41,109.92
(184.11V223.29) will arise, summing up to V83,541.86.
Costs of screening the TST negatives amount to V75,108.06
(639 [589 TST negatives plus 50 unread persons]V117.54).
In contrast to this strategy, in QFT based screening only
7.1% of all close contacts are QFT positive and subsequently
only about 3.6% would start IPT, resulting in costs of
V10,364.58 for screening of the 71 QFT positives
(71V145.98) and in costs of V8085.33 for the (rounded)
36 QFT positive persons with INH (36,21V223.29). From
this results a difference of V65,091.95 (cost of V83,541.86
due to TST positives minus V18,449.91 due to QFT posi-
tives) in favor of the QFT. However, the higher costs of QFT
negatives (929 persons with costs for the QFT V135,615.42
[V145.98 929] in contrast to costs of V75,108.06 for the
TST negatives as calculated above) adds V60,507.36, nearly
offsetting cost benefit of the QFT and resulting in only
a V4584.59 cost benefit to the QFT.
As a second CXR will be necessary in such cases, costs for
the rounded 177 (176.89) TST positives not willing to opt for
the IPT amount to V 8350.98 (V47.21 176.89), whilst only
35 (34.79) QFT positives (71 0.49V47.21) will so be
present, producing costs of V1642.44. This component of
contact investigation will again enlarge costs arising by TST
based screening in comparison to QFT based screening,
amounting to a cost difference of V11,293.13 (V6708.54
plus V4584.59).
Among the contacts with QFT based screening, under
baseline conditions, 5.1 (5.09) TB cases occur without
prevention, 2.1 (2.108) cases under prevention without
hepatitis and consequently full course of INH, i.e. 7.2
(7.198) cases in total. Choosing an alternative TST based
screening, 4.03 (4.033) TB cases will occur without
prevention, 1.67 (1.67068) cases (prevention without
hepatitis), 0.43 (0.433) cases due do unread TST results
(and subsequently no possibility for prevention), 1.645
cases due to false negative results of read TST and 0.0865
cases due to false negative results of unread TST, i.e.
a total of 0.67 cases (7.868 minus 7.198 cases) more than
with the QFT. This produces costs of V5578.23 within the
two-year period for cases not having been prevented, due
to false negative or unread TST results, under baseline
assumptions in comparison to the QFT based procedure.
In all cases and diagnostic modalities, costs for hepatitis
hospitalization or TB disease occurring in those abandoning
IPT due to hepatitis are small and do not influence the
outcome.
Combining both test procedures, currently a recommen-
dation not only in Germany,3 but inmost European countries,
applying QFT-G only after a positive TST result, gave costs at
V227.89 per screened contact, an additional cost of about
V12.10 per person compared with the QFT alone.
Dual testing dramatically lowers the costs associated
with the expected 620 negative screening results (589 plus
31) in comparison to the QFT by V17,632.8 [(V145.98 minus
V117.54); V28.44)], more than offsetting the additional
costs of QFT testing per TST positive contact of V43.24
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Table 2 GKV costs for INH treatment: medical and technical costs.
Medical services No. of
points
Point valuea Individual
payment
Frequency of
procedure
Payment
Doctor’s visit
Consultation fee (‘‘Ordinationskomplex’’)
per quarter (EBM 03111)
900 3.5085 cents V31.58 (rounded) 3 V94.74
Consultant fee for radiologists (EBM 24211) 125 3.5085 cents V4.39 (rounded) 1 V4.39
Laboratory services
Transport fee per case (EBM 40100), per quarter e e 2.6 3 V7.80
Creatinine [Jaffe method] (EBM 32066) e e 0.25 10 V2.50
Urea (EBM 32064) e e 0.25 10 V2.50
Blood count (EBM 32122) e e 1.1 10 V11
HIV serology (Immunoassay combination test) EBM 32575 e e 4.6 1 V4.60
Bilirubin total (EBM 32058) e e 0.25 1 V0.25
Gamma-GT (EBM 32071) e e 0.25 10 V2.50
GOT (EBM 32069) e e 0.25 10 V2.50
GPT (EBM 32070) e e 0.25 10 V2.50
Chest X-Ray (EBM 34220) 270 3.5085 cents V9.47 1 V9.47
Writing report after chest X-Ray (EBM 1600) 110 3.5085 cents V3.86 1 V3.86
EBM, Einheitlicher Bewertungsmaßstab (unified GKV cost table used in Germany)
a If no fixed price is stated (italics), average GKV point value for all costs types and service providers as stated by KBV in 2008.
1844 R. Diel et al.[V189.22 minus V145.98ZV43.24]. This sums up to
V15,609.64 from the 361 TST positive contacts who will
receive a QFT afterwards, resulting in a screening test cost
saving of about V2023.16 (V15,609.64 minus V17,632.80).
Similar savings of V2965.88 occurs when considering
screening and outcome costs of the 50 unread contacts,
summing to a V4989.04 saving for the dual approach.
However, cost for TB cases arising in the 2 years
following due to false negative or unread TST results
amount to about V18,021.02 and that is the main reason for
the higher costs of the dual step approach; as will occur in
the TST alone approach, 0.433 TB cases will arise due to the
19 unread persons expected to be positive, 0.0865 cases
due to the assumed false negatives among those 31 unread
persons expected to be negative, and 1.645 cases from the
589 read TST positive contacts who are falsely negative.
The sum of missed cases from the three sources is 2.1645,
which multiplied by V8325.72 per case, amounts to
V18,021.02 in cost for treatment of active TB.
Deterministic sensitivity analysis
Under baseline conditions in univariate sensitivity analysis
(Table 4), TST based screening becomes less costly relative
to QFT based screening if the proportion of test-positive
contacts willing to start IPT is less than 0.24 (23.8)%. This is
due to the trivial reason that a comparatively cheapTable 3 GKV costs for INH chemoprevention: medication.
Medicationa Cost/day (rounded) Duration (days)a Costs
INHb V0.26 270 V70.2
a Based on an average treatment period of 270 days using the
recommended maximum dose.
b Tebesium 300 Tbl 100 (N3), one tablet taken once a day.screening procedure will be less costly if a do-nothing
approach follows instead of preventing TB disease. TST
based screening would also be less expensive if the
proportion of IPT starters is decreased to the suggested
worst case of 20% and at the same time the price for the
TST vial (V7.5 per contact as baseline assumption)
increases by about 30% (V2.24). On the other hand,
decreasing the price for the single TST vial even by 50%, by
itself may not change the lower-cost position of the QFT
based screening and treatment under the baseline
assumption of a compliance of 51% (see Table 1).
Under baseline assumptions price for the QFT test (V40)
could even increase by 40% (V16.01), as the threshold of
V161.99 is needed for the total QFT screening procedure to
be equal to the costs of TST based screening. If in trivariate
sensitivity analysis the probability of opting for IPT were to
fall to 20% and the cost of the second CXR for non-compliers
were to be charged using only a base case amount without
applying the conventional complexity factor of 1.8, the
price for the QFT must be lowered by 18% to match the
costs for the TST based screening.
If the price of the QFT increases by 50% (and the price for
the second QFT in dual step-testing the same relation), both
performing the TST alone and the dual step TST/QFT-testing
would appear to be less expensive than QFT based screening
and treating alone, since the increasing net difference
between costs of QFT and TST would outweigh the costs of
non-prevented TB diseases under both TST strategies.
Increase in cost of treating TB disease by one third (up to
V12,488) makes the dual step strategy most expensive,
because the costs for failing to prevent the TB cases of the
3.42 persons changes the ranking of screening strategies.
QFT based screening is robust in most assumptions for
singularly varying costs of the TST, INH efficacy, INH-
induced hepatitis, cost of INH treatment, cost of TB disease
and second CXR for non-compliant individuals with respect
to IPT.
Table 4 Economic outcomes in deterministic sensitiviy analysis.
Variables Base-case Lower limit Upper limit
Total saving (cost) relative to TST screening, per 1000 close contacts, baseline assumptions, V
TST/QFT-G 4700 e e
QFT 16,800 e e
Cost per contact investigated, V
TST only 232.6 e e
QFT 215.8 e e
TST/QFT-G 227.9 e e
a) Varying cost of QFT-G (50%, i.e.  V20)
Total saving (cost) relative to TST screening, per 1000 close contacts, V
TST/QFT-G 4700 11,900 a3200
QFT 16,800 36,800 a2500
Cost per contact investigated, V
TST only 232.6 no change no change
QFT 215.8 195.8 (9.3%) 235.8 (þ8.5%)
TST/QFT-G 227.9 220.7 (3.2%)) 235.1 (þ3.1%)
Threshold V161.99 (þV16.01, i.e. 40% increase of QFT baseline costs of V40) until costs are equalized in comparison
with the TST base screening.
b) Varying cost of TST (50%, i.e.  V3.75)
Total saving (cost) relative to TST screening, per 1000 close contacts, V
TST/QFT-G 4700 4700 4700
QFT 16,800 13,010 20,550
Cost per contact investigated, V
TST only 232.6 228.8 (1.6%) 236.3 (þ1.6%)
QFT 215.8 no change no change
TST/QFT-G 227.9 224.1(1.7%) 231.6 (þ1.6%)
Threshold V: not available
c) Varying cost second chest ray (no factor; V26.23)
Total saving (cost) relative to TST screening, per 1000 close contacts, V
TST/QFT-G 4700 1700
QFT 16,800 13,800
Cost per contact investigated, V
TST only 232.6 228.9 (1.6%)
QFT 215.8 215.1 (0.3%)
TST/QFT-G 227.9 227.2 (0.3%)
Threshold V: not available
d) Varying cost second chest ray (no factor), decreasing option for QFT to 0.2 simultaneously and QFT costs for QFT (50%)
Total saving (cost) relative to TST screening, per 1000 close contacts, V
TST/QFT-G 4700 a11,500 a26,000
QFT 16,800 12.800 a27,200
Cost per contact investigated, V
TST only 232.6 219.6 (5.6%) 219.6 (e5.6%)
QFT 215.8 206.8 (4.2%) 246.8 (þ12.6%)
TST/QFT-G 227.9 231.1 (þ1.4%) 245.6 (þ7.2%)
Threshold V138.755 for the QFT based screening (7.205 for the QFT, i.e. minus 18% in comparison to theV 40 baseline)
e) Varying cost of TST (50%) and decreasing opting for QFT to 0.2 simultanoeusly)
Total saving (cost) relative to TST screening, per 1000 close contacts, V
TST/QFT-G 4700 a13,800 a13,800
QFT 16,800 6100 1400
Cost per contact investigated, V
TST only 232.6 221.9 (4.6%) 229.4 (1.4%)
QFT 215.8 228.0 (þ5.4%) 228.0 (þ5.4%)
TST/QFT-G 227.9 235.7 (þ3.3%) 243.2 (þ6.3%)
Threshold V119.88 for the TST based screening i.e. þV2.24 for the TST , i.e. plus 29.7% for the baseline TST vial
f) Varying cost of INH treatment (þ100%)
Total saving (cost) relative to TST screening, per 1000 close contacts, V
TST/QFT-G 38,000
QFT 49,700
(continued on next page)
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Table 4 (continued)
Variables Base-case Lower limit Upper limit
Cost per contact investigated, V
TST only 232.6 e 273.5 (þ15.0%)
QFT 215.8 e 223.8 (þ3.6%)
TST/QFT-G 227.9 e 235.5 (þ3.2%)
ThresholdV : not available
g) Varying cost of TB treatment (þ100%)
Total saving (cost) relative to TST screening, per 1000 close contacts, V
TST/QFT-G a4800
QFT 22,400
Cost per contact investigated, V
TST only 232.6 e 298.3 (þ22.0%)
QFT 215.8 e 275.9 (þ21.8%)
TST/QFT-G 227.9 e 303.1 (þ24.8%)
Threshold from V12,488 upwards the TST/QFT-strategy becomes most expensive
h) Varying cost of TB treatment (þ100%) and cost of INH treatment (þ100%)
Total saving (cost) relative to TST screening, per 1000 close contacts, V
TST/QFT-G 28.400
QFT 55,300
Cost per contact investigated, V
TST only 232.6 e 339.2 (þ31.4%)
QFT 215.8 e 283.9 (þ23.9%)
TST/QFT-G 227.9 e 310.8 (þ26.7%)
ThresholdV : not available
i) Decreasing probability of opting for INH treatment (0.2)
Total saving (cost) relative to TST screening, per 1000 close contacts, V
TST/QFT-G a13,900 e
QFT a2400 e
Cost per contact investigated, V
TST only 232.6 225.6 (3.0%)
QFT 215.8 228.0 (þ5.4%)
TST/QFT-G 227.9 239.5 (þ4.8%)
Threshold probabilityZ 0.238, before TST based screening becomes less expensive than with the QFT
k) Decreasing probability of opting for INH treatment (0.2) and doubling INH costs (þ100%)
Total saving (cost) relative to TST screening, per 1000 close contacts, V
TST/QFT-G a800
QFT 10,600
Cost per contact investigated, V
TST only 232.6 241.7 (þ3.8%)
QFT 215.8 231.1 (þ6.6%)
TST/QFT-G 227.9 242.5 (þ6.0%)
ThresholdV : not available
l) Lowering rate of progression to TB disease among QFT positives to that of the TST positives (0.0228)
Total saving (cost) relative to TST screening, per 1000 close contacts, V
TST/QFT-G 14.200 e
QFT 67.500 e
Cost per contact investigated, V
TST only 232.6 no change
QFT 215.8 165.1 (23.5%)
TST/QFT-G 227.9 218.4 (4.2%)
a Additional expenditure instead of saving.
1846 R. Diel et al.If the progression rate from LTBI to TB disease was
assumed to be the same for QFT testing as was the rate for
the TST (0.028) within the 2-y time-frame, the cost of QFT
alone amounted to only V165.06 per close contact, and
would save V 67.500, exceeding by more than 4 times the
savings of V16,791 per 1000 close contacts screened withTST alone under base case conditions (see Table 4). This
seemingly paradoxical amount of saving in favor of QFT is
due to the fact that costs for the lower number of arising TB
disease cases, given a progression rate of 0.0228 instead of
0.1464, will decrease remarkably: 84.4% fewer TB cases
among the a priori non-compliant contacts and 33.8% fewer
Enhanced cost-benefit analysis of strategies for LTBI screening and INH chemoprevention in Germany 1847TB cases e 40% of the total of TB cases that could not be
prevented despite of isoniazid preventive treatment
assuming an efficacy of 0.6e among the contacts under INH.
Probabilistic sensitivity analysis
In probability sensitivity analysis, the average expected value
for theQFT isV214.83 (standarddeviation [SD]V21.74)with
a median of V213.52, minimum of V162.5 and maximum of
V297.91). The average expected value of the TST is V233.04
with a SD ofV24.06), a median ofV231.79 at a minimum of
V170.51.70 and a maximum ofV316.53.
The mean for the TST/QFT strategy is V219.68 (SD
V25.11), with a median of V218.53, at a minimum of
V148.91 and a maximum of V328.71.
ThePSA simulation results demonstrate that theQFToption
is the least expensive strategy 53% of the time, exhibiting an
average expected value of V215.46 with a SD of V22.39.
Results of PSA for each single parameter in Table 1 show that
the most divergent parameter with respect to the baseline
assumptions is the probability of starting IPT, lying exactly
between worst case and base case value, subsequently
favouring both TST based strategies. Nevertheless, the TST/
QFTand TST strategies yield the lowest expected value only in
31.5% and 15.5%, respectively. These results implying that all
parameters are allowed to vary according to their distributions
simultaneously illustrate e in terms of stability e the relative
superiority of the QFT in screening for LTBI.
Discussion
Debates about sensitivity and specificity of the two tests for
LTBI flow from studies in active TB, acknowledged as at best
an imperfect measure of function in the true uses e
detecting LTBI, commonly in contact investigations. Cost or
cost-effectiveness analyses have thus been previously
compromised by ‘‘picking’’ results from individual cross-
sectional studies with different study populations and pool-
ing them to generate weighted mean test characteristics,
which at best are suppositions and depend on the prefer-
ences of the respective authors e.g.6,7 In contrast, we have
performed a cost analysis incorporating outcome data from
a prospectively observed cohort of close contacts, with
progression to disease as the ‘‘gold standard’’. Hereby, our
model used themost recent but also themost relevant datae
what actually happens in a contact setting e in order to
present amost reliable depiction of the possible alternatives
for a screening and treatment program of LTBI in Germany,
and to understand the weight of factors impacting any such
screening program implemented.
It is both obvious and demonstrated that the superior
specificity of an IGRA implies an important reduction in the
number of persons treated unnecessarily for LTBI, when the
tuberculin skin test is replaced with an IGRA. This will have
a strong impact on effectiveness of TB prevention programs in
termsofnumberneeded totreat (NNT)basedonanequivalent
risk of progression to TB disease, based on specificity alone.
This issue has been addressed in several cost or cost-effec-
tiveness analyses in the last few years e.g.8,9 and this advan-
tage has been seen as the defining capability of IGRAs in
comparison to the TST in terms of effectiveness. Our modelenhances the previous models in several ways: Firstly, incor-
porating a known predictive value re progression to active
disease by a positive test result improves the precision of the
comparison and thus of all resulting estimates. The result is
that the efficacy of the intervention itself is higher with the
more specific IGRA test, in so far as INH, if taken properly,
should reduce the number of TB cases in greater absolute
numbers than TST based intervention does.
Secondly, we incorporated the costs of public health
screening that come into effect if contacts do not take an
option for INH in terms of at least one second CXR in the
two years after exposure. This is consistent with the active
case finding approach inherent in the public health objec-
tive of breaking infection chains.
The comparative calculation of costs of TST- and QFT-
based screening reveal that our assumptions about higher TB
progressions risks givenapositiveQFT,basedonthepredictive
study results that were not available at the time of previous
analyses, produce remarkable reductions in the number of TB
cases even if less than one third (0.51 0.6) of QFT positive
contacts gain from INHpreventive treatmentpolicy. However,
this opportunity of preventing TB disease must be purchased
at the considerable cost of negative test results in the over-
whelming majority of screened close contacts. Thus e in
absolute terms e the cost difference between TST- and QFT-
based screening is obviously a decisive factor in our cost
analysis, and the leeway for rising prices of the QFT perfor-
mance is relatively lower than for the TST: Whereas the
threshold equalizing costs of both strategies is limited to a 40%
increase of QFT baseline costs (plusV16.01 in addition to the
V40oftheQFT),a50%price increaseof theTSTvialwouldonly
result in additional costs of 1.6% for the TST base strategy. On
the other hand, TST based screening is very sensitive to price
increases of IPT due to the far more frequent number of test-
positive individuals starting with INH: Doubling baseline costs
would lead to an cost increase for the TST based strategy of
15% in comparison to only 3.6% for the QFT based strategy.
Even decreasing the probability for starting INH to 20%, whilst
simultaneously increasing costs of INH by one half, would not
change the order of the strategies (QFT least expensive, TST
second, TST/QFT most expensive).
For the QFT based strategy, the most crucial determinant
for total costs is the compliance of test-positive contacts
starting on INH. If less than 24% of that group iswilling to begin
IPT, the advantages of a QFT based screening are gone. That
means that QFT should only be taken into consideration as
screening test if themedical infrastructure has been provided
to inform and accompany contact persons on their way to
a hopefully full INH course administered by established
pneumologists. From a public health perspective, we cannot
be satisfied with an evidence-based risk reduction of 60%
taking into account even longer durations of INH therapy than
6 months and comprising a more or less inevitable loss of
adherence in terms of routine effectiveness. We must
dramatically increasewillingness tobetreatedas thefirst step
in order to increase the potential for prevention of develop-
ment to active TB disease. With respect to this issue, our data
likely underestimates the true potential of INH chemo-
prevention because they are based solely on a TST-dominated
meta-analysis and worst case scenario. It is therefore prob-
able that the true effectiveness of an IPT program based on
the new test may be higher than we calculated: Sahni et al.10
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positive HCW who started IPT increased from 24% having
a positive TST result (of at least 15 mm) before implementa-
tion of the highly specific QFT to 52%, although they were not
close contacts of recent TB cases. Consequently, the paths of
contacts should have been modeled separately using a higher
and a lower probability of starting treatment in contacts
following a QFT- or TST based strategy, respectively.
Interestingly, neither increasing costs of IPT nor of TB
disease in sensitivity analysis had influence on the result that
the QFT-alone strategy is clearly less costly in comparison to
both TST based strategies, and no strategy was considerably
impaired by the very rare hepatotoxic side effects. Of note,
sensitivity analysis also demonstrated that the higher rate of
progression to TB disease among QFT positive contacts is not
the crucial point in influencing the ranking of screening and
treating strategies used in this cost-benefit analysis. Equal-
izing the respective rates for the QFT and the TST even
increased the difference of cost savings between the QFT
strategy on one hand and the dual step strategy or using the
TST alone on the other hand, due to the lower number of TB
diseases occurring in QFT positives. Our analysis can thus be
considered robust irrespective of the results of upcoming
longitudinal studies comparing the predictive values of the
two modalities in the future.Conclusions
Results suggest that QFT based screening is a not only
a more accurate indicator of progression to TB, it is also the
least expensive alternative for LTBI screening and treat-
ment. Within the first two years after exposure, among
contacts at high risk for developing TB disease, cost savings
of QFT based screening derive predominantly from higher
numbers of averted TB cases brought about by the avoid-
ance of false negative test results. These results would
remain robust even if no difference were assumed in the
progression rates of the TST positive and IGRA-positive
populations. Compliance with screening greatly affects QFT
benefit, with higher rates of compliance increasing the
potential for prevention of development to active TB
disease. Thus, this study has important implications for
convincing a larger proportion of clinical practitioners in
low-prevalence countries to adhere to the national
recommendations for practicing INH chemoprevention after
LTBI screening.Online supplement
Model specification
Our simulation model takes account of the observation that
progression to TB disease is more likely to occur in QFT-
positive than in TST positive subjects (see below). We
enlarged the prospective cohort of our study1 to a number
of 1000 close contacts of infectious TB source cases and
developed a decision-analytic tree model to trace the
clinical and economic outcomes for this cohort, which was
screened for LTBI by each of three possible testing strate-
gies: TST only, QFT only and dual step-testing (TST first,QFT-G only for those who are TST-positive as recommended
in the German national guidelines for contact tracing).3 The
pathways of events considered in the model are shown in
Figs. 1e3, whereas the whole cohort begins at time zero in
the contact state entering the tree from the left.
Under each screening strategy, the members of the
cohort testing positive (p_TST, p_QFT or p_QFT_TST posi-
tive) may or may not be started on IPT (p_Prev) and, as
a consequence, face differing probabilities of remaining
healthy or contracting TB disease (p_TB_TST or p_TB_QFT).
These probabilities depend on the progression rates
attributable to the respective screening procedure and the
protective effect of INH reaching its maximum after a full
course of 9 months (p_effect, see below). Persons testing
negative, irrespective of the screening test used, are
assumed not to be eligible for IPT. Before taking IPT,
persons suspected of having LTBI must have active TB
disease excluded by chest X-ray (CXR).
Contacts on INH therapy may have no hepatotoxicity, may
develop a drug induced hepatitis (p_hepatitis) and stop
therapy, giving an incomplete effect of IPT (p_partial effect).
Some suffer major complications requiring hospital admission
(p_hospital). Two outcomes are possible under hospitalization:
death due to hepatic failure (p_death_hep) or recovery.
Contacts who test negative for LTBI by using the TST are
considered uninfected with the exception of the proportion
that will be ‘false negative’, in comparison with simultaneous
positive QFT results as reported in the prospective study (see
above).
According to current recommendations in Germany,
test-positive contact individuals refusing IPT undergo
a second chest X-ray examination by a private radiologist
within the first year following LTBI diagnosis.
To perform the cost analysis, the total costs of the
procedures or clinical outcomes of each branch are accu-
mulated from left to right as to a basket and assigned as
payoff in the respective terminal nodes. Cost analysis for
each screening strategy were derived from multi-attribute
cost weightings using the decision analysis software pro-
gramme TreeAge Pro 2009 Healthcare Module, Release
1.0.1, TreeAge Software Inc., Williamstown, MA).
Health outcomes
Societal costs considered within 2 years, in which about 50%
of untreated cases are expected to occur after infection,11
were:
- Tuberculosis disease, including the cost of absenteeism
- Hospitalization due to INH-induced hepatitis
- Death due to INH-induced hepatitis
- Latent MTB infection without progression to disease
The latter category includes screening costs by the public
health service and costs for a second chest X-ray in contacts
not starting INH therapy to exclude active TB disease by
radiologists on behalf of the public health service.
Primary costs for IPT include GP visits, INH prescription,
diagnostic tests and referral to a radiologist at the end of
INH therapy to confirm the absence of progression to TB
disease. Only the share of cost reimbursed by the third-
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into account. For Germany, costs are reported in Euros (V),
for the reference year 2008. All costs were incurred within
a two-year timeframe so that discounting of costs to
present values was not necessary.
Sensitivity analyses
The sensitivity of the base case cost analysis results to input
parameters was explored by varying key parameters within
possible ranges, especially significant variables are ones
when varied through a reasonable range, result in a change
in the conclusion that would be drawn. Such deterministic
sensitivity analyses, including 1-way and 2- way analysis,
were performed on key model inputs.
Deterministic sensitivity analyses, however, have several
limitations. While multivariate analyses may also be con-
ducted by taking extreme values for several parameters, this
may not capture interactions between multiple inputs regu-
larily because it is generally not realistic to have all inputs at
their least or most favourable extremes. Thus, deterministic
multivariate analyses tend to overestimate uncertainty.
Statistical inferences cannot be made from deterministic
sensitivity analyses, although it may be helpful for decision
makers to know statistical distributions, or confidence inter-
vals, for the results. Probabilistic sensitivity analyses (PSA)
addresses these problems. Based on a Bayesian second order
MonteCarlo simulation the principle of PSA is to run themodel
a large number of times with different sets of inputs. This
requires assigning an appropriate statistical (probability)
distribution for all considered parameters that are not fixed
values in order to capture the possible range of outcomes.
Meanwhile, representing the state-of-the-art in the perfor-
mance of cost effectiveness analysis,4,5 for each run, inputs
are selected at random from their statistical distributions and
the simulation draws one value at a time from the feasible
range, doing so simultaneously for each parameter. In our
analysis we randomly picked a value for each variable from its
established distribution range. We did this for each of 1000
iterations and calculated mean values and standard devia-
tions. Beta distributions were assumed for probabilities,12,13
anduniform(fixed) and triangular distributionswerealso used
where appropriate. If not otherwise fixed, we doubled the
respective cost value and utilized the baseline and doubled
values as lowest and highest in uniform distribution with
respect to future rises.
Base case inputs, alternative values and the according
type of distribution are shown in Table 1.
Threshold analysis
By varying of several model parameters, we were able to
determine conditions under which a particular strategy
would be of lower cost relative to an alternative strategy.
Model inputs
Data were obtained from best-evidence based literature or
were calculated using the most recent national statistical
and epidemiological sources (e.g. Robert-Koch-Institute
and Federal Statistical Office) and German-specific cost
tarifs.Probability of progression to disease
The fast progression rate to disease (progression within two
years, in the absence of any intervention) was estimated
from1 where 601 close contacts of MTB-positive source
cases underwent both TST and QFT testing and were
subsequently observed for a mean of 103 weeks. For the
TST, 40.4% (243/601) of contacts were positive at a 5-mm
cutoff, whereas only 66 (11%) were QFT positive. Twenty-
five of the contacts with a positive QFT started, and in
regular fashion finished, IPT.
Of the 41 QFT positive, untreated subjects 14.63% pro-
gressed to TB disease within the 2-year follow-up period.
The progression rate for untreated TST positive subjects was
significantly lower at 2.28%, and one of the 219 untreated
TST negatives, who was, however, QFT positive, also pro-
gressed to disease. These progression rates with respect to
proportions for untreated QFT- and TST positives (41 QFT
positives/[601 minus 25 treated contacts], i.e. 0.0711, and
219 TST positives/[601minus 24 treated TST positive
contacts], i.e. 0.380) resulting in a ratio of QFT positives to
TST positives of 0.1872 were used in our model and
normalized to a model cohort of 1000 contacts to be
screened. Whereas false negative QFT results were not
considered as only QFT positives developed TB disease, 44 of
the 358 (577e219) TST negative contacts (must have been
false negative assuming the same progression rate to disease
as among the TST positives resulting in one case of TB (1/
0.0228Z 43.86 contacts). Thus, the probability of being
falsely negative given a negative TST is 43.86/358Z 0.1225.
Normalized to 1000 contacts the number of TB cases in
QFT positives arising without treatment in the time frame
of two years is 1000 0.0711 0.1463Z 10.40.
Rates of starting therapy
Most studies do not mention separately the number of
contacts eligible for treatment and those willing to start
treatment. According to the report of14 we took into consid-
eration only about one half (51%, 116/227) of the full range of
rates of contacts eligible for INH therapy as a conservative
estimation. However, poor adherence (20%) with a complete
regimen has previously been reported among high-risk resi-
dents in a large inner cityproject.15Weused this proportionas
worst case and in univariate sensitivity analysis for the
respective number of test-positives (QFT and TST).
Frequency and onset of hepatitis
10% to 20% of patients on IPT experience transient asymp-
tomatic elevations of serum aminotransferase levels but
carry no increased risk for hepatitis16; their elevated levels
regularly recede again spontaneously. Clinical hepatitis,
defined by the presence of both symptoms and any
abnormal transaminase level,17 is much less common and is
rarely fatal, particularly when recommendations for
surveillance are followed.
To date, there are only two meta-analyses available that
address the rate of INH-induced hepatitis in adults: The first
one by Steele et al.18 reviewed 6 very different studies on
the incidence of hepatitis in adults taking INH therapy
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provided a summary rate of clinical hepatitis of 0.6% (6 per
1000 patients).
The meta-analysis of the Cochrane group,19 using only
randomized studies and fulfilling evidence-based criteria of
a meta-analysis, only selected one study, the IUAT Eastern
Europe study.20 There, patients had a rate of INH-associ-
ated hepatotoxicity in 0.36% (6 months treatment) and
0.52% (12 months treatment) based on related clinical
symptoms. Hepatotoxicity was therefore observed in a total
of 95 of 20,840 patients receiving INH (0.46%). For practical
purposes we used a proportion of 0.5 (i.e. 5 of 1000 persons
receiving INH, p_hepatitisZ 0.005) in our analysis but
0.36% and 0.52% in sensitivity analysis.
The biggest prospective single study determining the
incidence of INH-hepatitis is the early United States Public
Health Service (USPHS) study of 1971 to 197321 that docu-
mented 236 suspected cases among 13,838 receiving INH.
Here, the onset of INH-hepatitis was distributed throughout
the entire 12 months, but about one half occurred early,
within three months, further 25 percent between 3e6
months and the remaining 35 percent between 6e12
months. Thus, for modeling purposes we estimated that
hepatitis would manifest at the time median, i.e. at the
end of three months of treatment.
Fatal isoniazid hepatitis and need for
hospitalization
The USPHS study also showed an unexpectedly high rate of
fatal isoniazid hepatitis, eight deaths (0.06 percent) among
the 13.838 persons. All of the deaths were in patients older
than 35, and most were in patients with severe alcoholism
who were not being routinely monitored for liver function
abnormalities. In contrast, subsequent studies published in
the 90s involving more than one million persons treated
with INH have reported hospitalization rates of 0.1e0.2
hospitalizations per 1000 persons starting treatment
(median, 0.15 hospitalizations per 1000 persons) and
mortality rates of 0e0.3 deaths per 1000 persons starting
treatment (median, 0.04 deaths per 1000 persons).18,22e25
Again, we used these medians as probabilities in our model.
Given a probability of 5 per 1000 persons for INH-induced
hepatitis and 0.15 hospitalizations for the same size, the
probability of hospitalizations following hepatitis is 0.15/
5Z 0.03) and the probability of death due to INH-induced
hepatitis following hospitalization 0.04/0.15Z 0.267).
Since liver transplantations are very rare, not routinely
available, they were not included in our analysis.
Minor non-hepatotoxic side effects of INH, that were
reported infrequently in a few percent including mild and
transient headache, nausea, and dizziness and therefore
are rarely a cause of discontinuing treatment,26 were also
not taken into account in our analysis.
Efficacy and effectiveness of isoniazid
chemoprevention
The efficacy of INH in preventing TB is well established
through a series of randomized controlled trials which have
been analyzed in Cochrane meta-analysis.19 This groupincluded 11 studies involving 73,375 patients who met the
inclusion criteria. In 10 of the 11 studies, INH taken daily for
6 to 12 months reduced the occurrence of active TB cases
over the follow-up period (two years or longer). Amongst
the total of 73,375 patients randomized to INH or placebo,
796 developed disease. Tuberculosis developed in 239 cases
randomized to INH and in 557 cases randomized to placebo,
for a relative risk (RR) of 0.40, i.e. a reduction of TB cases
compared to placebo of 60%. In contrast to the historical
Bethel studies of Comstock27 resulting in an up to 90%
reduction of TB cases in the subgroup of ‘‘completer-
compliers’’ (taking at least 80% of the recommended INH
dose) this low percentage in the pooled Cochran data may
be explained by the more representative, heterogeneous
degrees of adherence of the study populations to their
regimes, varying from 38%28 and 40%29 up to 80%,30 thus in
fact not addressing ‘‘efficacy’’ under ideal conditions but
investigates routine ‘‘effectiveness’’ instead.
Furthermore, its results already takes into account
a certain amount of INH resistance resulting in no benefit of
INH chemoprevention among contacts whose latent TB
infection is INH resistant. In the five studies in the Cochrane
paper that reported INH resistance, 9 isolates from 137
patients (6.6%) taking placebo were INH resistant,
compared with 13 isolates from 63 patients (20.6%) taking
INH.11 This figure is comparable to the current INH resis-
tance in strains of Mycobacterium tuberculosis in Germany
of about 10% (8.0% only against INH plus 2.3% together with
Rifampicine (RMP).31
Therewas thus little need for further reducing the level of
this baseline protective effect by separately choosing esti-
mates of the rate of patients completing chemoprevention or
additionally incorporating INH resistance figures for
modeling. The figure of having only a 60% protective efficacy
replaces theprocedureof earlier cost-effectiveness analyses
that used a higher effect of 80% as baseline and multiplied
this estimate by completion rates of e.g. 80% in.32
Partial efficacy in incomplete therapy
due to hepatitis
In the randomized double-blind controlled IUAT trial20
there was a protective effect of INH even when the drug
was taken for only 3 months. The investigators reported
a reduction of more than 21 % in TB cases compared with
placebo in the follow-up period of five years (76 cases
among 6956 persons taking INH vs 97 cases of 6990 persons
taking placebo, equivalent to a risk reduction of 21.6%). We
suggested that episodes of hepatitis would lead to the
stopping of IPT and accordingly to the mean onset after
three months (see above). We therefore used a value of 21%
for the efficacy of an incomplete course (p_partial_effect)
and explored the upper and under limit of 95% CI as ranges
in univariate sensitivity analysis. Persons stopping chemo-
prevention before 3 months therapy were not assigned
a protective benefit, for lack of evidence.
Costs
Costs were analyzed from the societal perspective
comprising direct costs for the health care system borne by
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absenteeism. Costs are reported in Euros (V), and for the
reference years 2008/2009. Costs were considered over
only two years, so the need for discounting did not arise.
Cost of treatment TB disease
Since the last German cost of burden analysis for tubercu-
losis33 epidemiological data as well as cost figures have
changed remarkably. In 2006, only 66.8% of the 5402 TB cases
in adults aged 15 years or older were treated in lung wards or
special lung clinics (and afterwards by settled doctors,31 and
the average duration of stay in hospital was only 28 days.34
Using the latest available data, costs for medication
(quadruple therapy) for out-patient as assigned in33 had tobe
recalculated resulting in V741.03 for a complete six month-
course (180 days) of outpatient therapy and V554.57 for
a post-hospital therapy immediately following hospital-
isation (180 28 days). Medical and technical costs using the
new German Einheitlicher Bewertungsmaßstab (EBM) 2009
come into effect since 1 January 200935 areV381.79 for a full
course of outpatient therapy for culture confirmed pulmo-
nary TB cases and only V290.29 for closed pulmonary TB.
79.5% of all pulmonary TB cases were culture confirmed,31
i.e. the weighted mean between cost of culture confirmed
and non-infectious TB cases was V363.03 (V381.79 0.795
plus V290.29 0.205). Medical and technical costs for post-
hospitalization treatment were V280.72 for culture
confirmed cases and V217.95 for closed TB. Accordingly, the
weighted mean was V267.9 (V280.72 0.795 plus
V217.95 0.205).
As far as inpatients are concerned, since 1 January 2004
hospital costs are based on the uniform German G-DRG
system, which allocates each case to a diagnosis-related
group. A calculated base rate for the hospitals in the cor-
responding federal state is then multiplied by the specific
cost weight of a disease, resulting in the proceeds for the
hospital providing the treatment.
Whilst the costs for E 76 B cases (without severe
complications, hospital stay less than 14 days) and E 76 C
cases (with severe complications, hospital stay less than 14
days), are fixed, the costs per day for patients being diag-
nosed and treated in hospital for longer than 14 days (E76A)
have to be negotiated separately between third-party
payers and the respective hospital and may vary as a result.
However, the relationship between numbers of patients
falling into the three DRGs have not yet been evaluated and
therefore are unknown. The average hospital costs per
patient staying at least 14 days or longer in hospital
throughout the country were V7288.81 in 2007 (Deutsche
Krankenhaus Gesellschaft, internal evaluation, communi-
cated 18.11.2008). Although it may overestimate the real
hospital costs we took this value for all hospital patients for
lack of further data for short-staying patients.
Thus, in total, the direct costs for pulmonary TB can be
calculated as follows: Medical costs for outpatient treat-
ment V741.03 plus V363.03 (medical and technical
costs)ZV1104.06; inpatient treatment V7288.81 plus
medication costs of V554.57 and medical and technical
costs for post hospitalization outpatient treatment of
V267.9ZV8111.28. The weighted mean between primarilyinpatient treatment and complete outpatient treatment is
V8111.28 0.668 plus V1104.06 0.332ZV5784.88.
From a societal point of view losses in productivity due to
disease must be included in disease cost estimatates. In
accordance with the human capital approach, indirect costs
refer to the production loss for the economy at large caused
by absence from the workplace on sick leave. According to
the Hanoverian Consensus,36 the productivity losses caused
by sickness should be evaluated without consideration of
differences in the branches, differences in age or sex, with
the average gross income for the period from non-self-
employed employment. The average productivity loss to
cover the self-employed as well is calculated as follows:
productivity lossZ sick leave days [gross income from
non-self-employed work: (no. of dependent gainfully
employed 365 days)]. For 2007 the loss of productivity in
Germany is considered to be V91.81 per sick leave day.37
The sick leave duration in 2006 for mandatory members of
the AOK throughout Germany for lung TB (ICD-10 A15 and A16)
was on average 42,001 days/1018 casesZ 41.26 days per
case.38 The gainfully employed in the mandatory age group
(15e64 years) was 67.5%. Therefore, the loss of productivity
per personwasV91.81 41 days (rounded),multiplied by the
proportion of employees in 2006 ( 0.675)ZV2540.84.
The total costs per case of pulmonary TB is V5784.88
plus V2540.84ZV8325.72.
Cost of public health screening for LTBI
The responsibility for diagnosis of LTBI before sending
a screened contact to pneumologists in private practice lies
with the public health service. Public health offices routinely
perform contact investigations according to x16 and x25 para
of the Contagion Protection Law (IfSG). As demonstrated
in39, the cost of testing comprised the labor cost for the staff
performing the Mantoux TST, the material cost of the vial
and associated consumables for each TST, and the costs of an
initial chest radiograph to rule out active TB prior to treat-
ment and a medical consultation at the end of screening is
V117.54 (based on an average price for a TST vial ofV 7.50).
It was assumed that the TST was read in 95% of the tested
contacts. For the QFT-G assay, besides the costs for a chest
radiograph and consultation, the cost for drawing blood, the
cost of the screening kit, reagents, and laboratory techni-
cian’s fees for each QFT-G assay test have to be considered
(V145.98, based on an average price of V40 for performing
the QFT). For the dual step strategy (TST first, QFT second),
the chest X-ray costs were charged only for the first step
(TST), resulting in partial QFT-G costs ofV71.68. These costs
have to be added to the costs before taking subsequent IPT
into account. For sensitivity analysis costs for the TST vial
and QFT performance were changed by 50%, i.e. V3.75 e
V11.25 for the TST and V20 e V60 for the QFT.
Cost of IPT
In accordance with the current German guidelines, contacts
aged below 50 years need to visit a physician every month
for examination (including a brief checking for signs of
hepatitis, such as dark urine and ikterus) and be closely
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analyses include periodic liver values (ALT, AST, GGT), renal
retention parameters (creatine, urea) and blood count at
baseline before starting treatment and then every four
weeks through the end of the therapy (Table 2). The stan-
dard bilirubin check need not be repeated if there are no
anomalies in the initial liver parameters. HIV serology
should be determined as the presence of a HIV infection
would require a prolonged (12-month) IPT regimen.
Asymptomatic serum AT increases are expected and usually
do not indicate that treatment need be stopped. INH drug
costs in our model were based on the cheapest available
drug with the corresponding active substance according to
the 2008 issue of the German Rote Liste. The package size
was adjusted for the number of treatment days (Table 3).
Close contacts undergo chest radiography not only before
beginning prevention (which has already been performed by
the public health service) but also at the end (that will be
charged here). For IPT, therefore, pneumologists’ fees and
laboratory costs amount to V148.61, the costs of INH for 9
months areV74.68, i.e. in total IPT costs ofV223.29. Where
INH chemoprevention is discontinued after three months,
costs amount to onlyV73.32, a reduction coming principally
fromthe costs for twobasicGPcharges (oneper quarter) that
will not occur for the second and third quarter of therapy and
the absence of a charge for the final chest X-ray
Cost of hepatotoxic side effects
For minor hepatotoxic complications, costs of additional
consultations and laboratory tests do not arise because of
the close monitoring of symptoms and periodic liver values
as described above and no longer-term health deficit is
assumed to occur. In case of the need of hospitalization due
to INH-induced hepatitis, according to the German DRG
2009 (base case value: V2800, certified web grouper), costs
of V1433.6 arise (K71.6: toxic hepatitis; Y57.9: complica-
tions from drugs; DRG H63C; PCCL 0).
For costs of death to further complication, i.e. INH-
induced liver failure (H63A; PCCL 3; K72.0: acute and
subacute liver failure; Y57.9: complications from drugs;
K72.74: hepatic encephalopathy, degree 4, and J96.0:
acute respiratory insufficieny), costs are V3883.6 per case.
Cost of second chest X-ray (if there is no IPT)
According to the German scale of fees for medical doctors
(GOA¨), dated October 2007, Number 5137, two views, (450
points, point value 5.82873 Cent Z V26.23) multiplied by
a complexity factor of 1.8 (dependent on agreement
between public health service and radiologist) is V47.21.
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